Article
Selective retina therapy for chronic central serous chorioretinopathy (B)
Search Medline for
Authors
Published: | June 9, 2015 |
---|
Outline
Text
Purpose: To evaluate the visual and anatomical outcomes in patient with chronic central serous chorioretinopathy (CSC) after selective reinta therapy (SRT).
Methods: We included 12 eyes of 12 patients with chronic CSC patients at least 3 months retrospectively. Following evaluation of test spots at temporal vessel arcades, SRT (Q-switched, Nd:YLF laser, wave length 527 nm, pulse duration 1.7 µs) was applied to the surrounding areas of leakage observed on fluorescein angiogram and/or pigment epithelial detachments (PED). Due to the invisibility of SRT spots, both reflectometry and optoacoustic method were used as method of dosimetry. Changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and macular sensitivity by microperimetry were evaluated. The Wilcoxon signed rank test was used for analysis.
Results: Eyes received a mean of 3.5 treatment spots at the pulse energy of 65u µJ to 90 µJ. The follow-up period ranged from 4 to 12 months. Subretinal fluid (SRF) completely resolved in 75% (9 eyes) at 3 months. Retreatment was performed in 4 eyes, resulting in 91.6% (11 eyes) having complete resolution of SRF at 4 months and one eye received two additional treatments resulting in complete resolution at 7 months. PED was flattened in 4 eyes at 3 months. Mean BCVA (logMAR) improved from 0.23 at baseline to 0.12 at month 3 (P=0.035). CMT decreased from 341.4 µm at baseline to 236.0 µm at 3. Months (P=0.008). There was no evidence of scotomatous changes around SRT-treated lesions demonstrated by microperimetry.
Conclusions: We firstly demonstrated that SRT treatment could flatten PED and resolve SRF in chronic CSC patients by using indirect targeting technique.